[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/trimod-therapeutics” connections=”true” suffix=””]

TriMods proprietary TriMoVav technology is a pre-clinically validated technology that uses the patients own immune system, to target tumours and promotes its eradication by attenuating its immune subversion strategies using a combination of (1) a TLR agonist; (2) a kinase inhibitor; and (3) a tumour antigen of choice. This combination immunotherapy directs the bodys immune system to seek out and destroy tumours present in the body by allowing the selective inhibition of the immunosuppressive, anti-inflammatory and Treg-promoting arm of the innate response.